|
| Press Releases |
|
 |
|
| Tuesday, May 28, 2024 |
|
|
CR Pharmaceutical Armed with Leading Advantages Releases Growth Potential and Achieves High-quality Sustainable Development |
| China Resources Pharmaceutical Group Limited ("CR Pharmaceutical" or the "Group") (stock code: 3320.HK), recorded total revenue of RMB244,703.9 million last year, a 12.2% climb year-on-year, and net profit of RMB 7,775.0 million, a 16.8% increase year-on-year. more info >> |
|
| Monday, November 14, 2022 |
|
|
CR Pharmaceutical Becomes Constituent of MSCI China Index Once Again |
| China Resources Pharmaceutical Group Limited ("CR Pharmaceutical" or the "Group") (stock code: 3320) has announced that the Group will once again be included as a constituent stock of the MSCI China Index, which will become effective after the market close on 30 November 2022. more info >> |
|
| Monday, January 20, 2020 |
|
|
安捷證券第二輪藥品集採結果：降價主旋律不變，首推創新型龍頭 |
| 2020年01月17日，第二輪國家集採正式開標，結果如下：122家企業參與採購，33個(按通用名計)藥品的194個品規激烈厮殺，價格降幅超出市場預期。 more info >> |
|
| Tuesday, July 2, 2019 |
|
|
华润医药再度蝉联资本杰出中国企业成就奖 |
华润医药集团有限公司（「华润医药」或「集团」；股份编号：3320）欣然宣布，集团于《资本杂志》主办的第十四届「资本杰出中国企业成就奖」中再度获选为「资本杰出中国医药集团」，彰显集团在过去一年于业务上的杰出表现及其稳固的发展潜力。
more info >> |
|
|
華潤醫藥再度蟬聯資本傑出中國企業成就獎 |
華潤醫藥集團有限公司（「華潤醫藥」或「集團」；股份編號：3320）欣然宣佈，集團於《資本雜誌》主辦的第十四屆「資本傑出中國企業成就獎」中再度獲選為「資本傑出中國醫藥集團」，彰顯集團在過去一年於業務上的傑出表現及其穩固的發展潛力。
more info >> |
|
| Friday, August 25, 2017 |
|
|
华润医药中期业绩增长理想 实现收益约港币827亿元 |
| 华润医药集团有限公司（「华润医药」）或「集团」；股份编号：3320）公布截至2017年6月30日止年度（「期内」）的中期业绩。 more info >> |
|
|
華潤醫藥中期業績增長理想 實現收益約港幣827億元 |
| 華潤醫藥集團有限公司（「華潤醫藥」）或「集團」；股份編號：3320）公佈截至2017年6月30日止年度（「期內」）的中期業績。 more info >> |
|
|
China Resources Pharmaceutical Delivers Solid Interim Results; Half-year Revenue Reaches HK$82.7 Billion |
| China Resources Pharmaceutical Group Limited ("CR Pharmaceutical" or the "Group") (stock code: 3320), announced its interim results for the six months ended 30 June 2017 ("Reporting Period"). more info >> |
|
| Monday, March 20, 2017 |
|
|
华润医药全年业绩稳健增长 实现收益约港币1,567亿元 |
华润医药集团有限公司（「华润医药」）或「集团」；股份编号：3320）公布截至2016年12月31日止年度（「年内」）的全年业绩。
more info >> |
|
|
華潤醫藥全年業績穩健增長 實現收益約港幣1,567億元 |
華潤醫藥集團有限公司（「華潤醫藥」）或「集團」；股份編號：3320）公佈截至2016年12月31日止年度（「年內」）的全年業績。
more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Buy International Homes at the Global Property Expo, Singapore
Jul 15, 2025 20:06 HKT/SGT
|
|
|
XDS Datacentres signs 15-year deal to host 10MW of AI workloads in Saudi's Desert Dragons facilities
Jul 15, 2025 19:41 HKT/SGT
|
|
|
U.S. Polo Assn. Celebrates Seventh Year Supporting the 2025 Outsourcing Inc. Royal Charity Polo Cup
Jul 15, 2025 19:00 HKT/SGT
|
|
|
Ocean One Seizing Business Opportunities with Main Board Listing Application
Jul 15, 2025 19:00 HKT/SGT
|
|
|
大洋環球申轉主板上市捉緊商機 迎中國恢復部分日本水產進口機遇
Jul 15, 2025 18:22 HKT/SGT
|
|
|
大洋环球申转主板上市捉紧商机 迎中国恢复部分日本水产进口机遇
Jul 15, 2025 18:10 HKT/SGT
|
|
|
雲頂新耀股價創階段新高 通用型現貨腫瘤治療性疫苗EVM14「中美雙報」再釋mRNA平台潛力
Jul 15, 2025 17:40 HKT/SGT
|
|
|
云顶新耀股价创阶段新高 通用型现货肿瘤治疗性疫苗EVM14"中美双报"再释mRNA平台潜力
Jul 15, 2025 17:34 HKT/SGT
|
|
|
耀啟新程！康哲藥業今日於新加坡交易所主板實現二次上市
Jul 15, 2025 17:05 HKT/SGT
|
|
|
AATec Medical and Northway Biotech Announce Partnership to Develop Industrial Production Process for ATL-105 Targeting Lung Disease
Jul 15, 2025 17:00: JST
|
|
|
耀启新程！康哲药业今日于新加坡交易所主板实现二次上市
Jul 15, 2025 16:53 HKT/SGT
|
|
|
AATec Medical and Northway Biotech Announce Partnership to Develop Industrial Production Process for ATL-105 Targeting Lung Disease
Jul 15, 2025 16:00 HKT/SGT
|
|
|
ONERHT Foundation Announces 8th edition of GAIL Forum which will focus on Green Leadership in ASEAN
Jul 15, 2025 13:00 HKT/SGT
|
|
|
PCG Collaborates with Big Boss Taxi and STAY BAR to Usher in a Cashless Era
Jul 15, 2025 12:30 HKT/SGT
|
|
|
交易寶攜手Big Boss Taxi與STAY BAR開啟無現金新時代
Jul 15, 2025 12:30 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
